Naitoh Keiko, Kamigaki Takashi, Matsuda Eriko, Ibe Hiroshi, Okada Sachiko, Oguma Eri, Kinoshita Yoshihiro, Takimoto Rishu, Makita Kaori, Ogasawara Shun, Goto Shigenori
Seta Clinic, Tokyo, Japan
Seta Clinic, Tokyo, Japan.
Anticancer Res. 2016 Jul;36(7):3715-24.
For a peptide-pulsed dendritic cell (DC) vaccine to work effectively in cancer treatment, it is significant that the target protein is expressed in cancer cells. Wilms' tumor 1 (WT1) has been identified as a molecular target for immune cell therapy of cancer. We evaluated the protein expression levels of WT1 in various solid tumors, as well as mucin 1 (MUC1) or major histocompatibility complex (MHC) class l molecules. Seven hundred and thirty-eight patients whose tissue samples were examined by immunohistochemical analysis agreed to undergo DC vaccine therapy. The positive staining of WT1 in tumor cells was observed in 25.3% of patients, with only 8.5% of them showing moderate to strong expression; moreover, WT1 tended to localize in the nucleus and cytoplasm. A positive staining of tumor cells by an anti-MHC class l monoclonal antibody was observed in 98.6% and by an anti-MUC1 monoclonal antibody in 76.8% of the patients. In relation to the application of cancer-specific immunotherapy, these findings provide useful information for determining the efficacy of MUC1- and WT1-targeted therapy.
为使肽脉冲树突状细胞（DC）疫苗在癌症治疗中有效发挥作用，靶蛋白在癌细胞中表达至关重要。肾母细胞瘤1（WT1）已被确定为癌症免疫细胞治疗的分子靶点。我们评估了WT1以及黏蛋白1（MUC1）或主要组织相容性复合体（MHC）I类分子在各种实体瘤中的蛋白表达水平。738例接受免疫组化分析检测组织样本的患者同意接受DC疫苗治疗。在25.3%的患者肿瘤细胞中观察到WT1阳性染色，其中只有8.5%表现为中度至强表达；此外，WT1倾向于定位于细胞核和细胞质。在98.6%的患者中观察到抗MHC I类单克隆抗体对肿瘤细胞的阳性染色，在76.8%的患者中观察到抗MUC1单克隆抗体的阳性染色。关于癌症特异性免疫疗法的应用，这些发现为确定MUC1和WT1靶向治疗的疗效提供了有用信息。
